Secondary Prevention of Atherosclerosis through Chlamydia pneumoniae Eradication (SPACE Trial): A randomised clinical trial in patients with peripheral arterial disease

European Journal of Vascular and Endovascular Surgery

Volumn 29, Issue 4, 2005, Pages 403-411

  Vainas, Tryfon ^a,b   Stassen, F R M ^a,b   Schurink, G W H ^a,b   Tordoir, J H M ^a,b   Welten, R J Th J ^c   van den Akker, L H J M ^c   Kurvers, H A J M ^a,b   Bruggeman, C A ^a,b   Kitslaar, P J E H M ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c Sittard Geleen Heerlen   (Netherlands)

Author keywords

Atherosclerosis; Azithromycin; Chlamydia pneumoniae; Peripheral vascular disease; Randomised clinical trial

Indexed keywords

ANTITHROMBOCYTIC AGENT; AZITHROMYCIN; IMMUNOGLOBULIN A; PLACEBO;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ATHEROSCLEROSIS; BACTERIAL INFECTION; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTERMITTENT CLAUDICATION; LEG REVASCULARIZATION; LIFE TABLE; LIMB ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SEROLOGY; STROKE; SURVIVAL RATE; SYMPTOMATOLOGY; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

AGED; ANTI-BACTERIAL AGENTS; ARTERIOSCLEROSIS; AZITHROMYCIN; CHI-SQUARE DISTRIBUTION; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 14744293018     PISSN: 10785884     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejvs.2005.01.001     Document Type: Article

References (51)

1. R. Ross Atherosclerosis - an inflammatory disease [see comments] N Engl J Med 340 1999 115-126
2. W. Ophuls Arteriosclerosis and cardiovascular disease: Their relation to infectious diseases JAMA 76 1921 700-701
3. C. Frothingham The relationship between acute infectious diseases and arterial lesions Arch Intern Med 8 1911 153-162
4. W. Osler Diseases of the Irteries In: W. Osler, ed. Modern medicine: its practice and theory 1908 Lea and Febiger Philadelphia 429-447
5. C.G. Fabricant J. Fabricant M.M. Litrenta C.R. Minick Virus-induced atherosclerosis J Exp Med 148 1978 335-340
6. D.H. Spodick A.P. Flessas M.M. Johnson Association of acute respiratory symptoms with onset of acute myocardial infarction: Prospective investigation of 150 consecutive patients and matched control patients Am J Cardiol 53 1984 481-482
7. E. Pesonen O. Siitonen Acute myocardial infarction precipitated by infectious disease Am Heart J 101 1981 512-513
8. P. Saikku M. Leinonen K. Mattila M.R. Ekman M.S. Nieminen P.H. Makela J.K. Huttunen V. Valtonen Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction Lancet 2 1988 983-986
9. C.C. Kuo A. Shor L.A. Campbell H. Fukushi D.L. Patton J.T. Grayston Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries J Infect Dis 167 1993 841-849
10. E. Gurfinkel G. Bozovich A. Daroca E. Beck B. Mautner Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group [see comments] Lancet 350 1997 404-407
11. S. Gupta E.W. Leatham D. Carrington M.A. Mendall J.C. Kaski A.J. Camm Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction Circulation 96 1997 404-407
12. J.B. Muhlestein J.L. Anderson J.F. Carlquist K. Salunkhe B.D. Horne R.R. Pearson et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study Circulation 102 2000 1755-1760
13. C.M. O'Connor M.W. Dunne M.A. Pfeffer J.B. Muhlestein L. Yao S. Gupta R.J. Benner et al. Azithromycin for the secondary prevention of coronary heart diseasA events: The WIZARD study: a randomized controlled trial JAMA 290 2003 1459-1466
14. R. Zahn S. Schneider B. Frilling K. Seidl U. Tebbe M. Weber et al. for the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausarzte (Working Group of Leading Hospital Cardiologists; ALKK). Antibiotic therapy after acute myocardial infarction: A prospective randomized study Circulation 107 2003 1253-1259
15. C. Diehm A. Schuster J.R. Allenberg H. Darius R. Haberl S. Lange et al. High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: Cross-sectional study Atherosclerosis 172 2004 95-105
16. A.P. Meyer C. Bril-Bazuin H. Mattie P.J. van den Broek Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus Antimicrob Agents Chemother 37 1993 2318-2322
17. C.J. Dunn L.B. Barradell Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections Drugs 51 1996 483-505
18. World Medical Association Declaration of Helsinki Recommendations guiding physicians in biomedical research involving human subjects Cardiovasc Res 35 1997 2-3
19. J.A. Dormandy G.D. Murray The fate of the claudicant - a prospective study of 1969 claudicants Eur J Vasc Surg 5 1991 131-133
20. S.S. Gottliep Dead is dead-artificial definitions are no substitute Lancet 349 1997 662-663
21. T. Vainas R. de Graaf F.R. Stassen H.A. Kurvers G.E. Grauls P.J. Kitslaar et al. Chlamydia pneumoniae serology: Comparing a commercial enzyme immunoassay and microimmunofluorescence test in patients with cardiovascular disease APMIS 111 2003 363-369
22. S.F. Dowell R.W. Peeling J. Boman G.M. Carlone B.S. Fields J. Guarner et al. Standardizing Chlamydia pneumoniae assays: Recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada) Clin Infect Dis 33 2001 492-503
23. T. Vainas H.A. Kurvers W.H. Mess R. de Graaf R. Ezzahiri J.H. Tordoir et al. Chlamydia pneumoniae serology is associated with thrombosis-related but not with plaque-related microembolization during carotid endarterectomy Stroke 33 2002 1249-1254
24. D. Sander K. Winbeck J. Klingelhofer T. Etgen B. Conrad Enhanced progression of early carotid atherosclerosis is related to Chlamydia pneumoniae (Taiwan acute respiratory) seropositivity Circulation 103 2001 1390-1395
25. H.S. Markus M. Sitzer D. Carrington M.A. Mendall H. Steinmetz Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis Circulation 100 1999 832-837
26. B. Cercek P.K. Shah M. Noc D. Zahger U. Zeymer S. Matetzky et al. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the azithromycin in acute coronary syndrome (AZACS) trial: A randomised controlled trial Lancet 361 2003 809-813
27. P. Wiesli W. Czerwenka A. Meniconi F.E. Maly U. Hoffmann W. Vetter et al. Roxithromycin treatment prevents progression of peripheral arterial occlusive disease in Chlamydia pneumoniae seropositive men: A randomized, double-blind, placebo-controlled trial Circulation 105 2002 2646-2652
28. A.F. Stone M.A. Mendall J.C. Kaski T.M. Edger P. Risley J. Poloniecki et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA) Circulation 106 2002 1219-1223
29. J. Sinisalo K. Mattila V. Valtonen O. Anttonen J. Juvonen J. Melin et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome Circulation 105 2002 1555-1560
30. F. Neumann A. Kastrati T. Miethke G. Pogatsa-Murray J. Mehilli C. Valina et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebo-controlled trial Lancet 357 2001 2085-2089
31. D. Sander K. Winbeck J. Klingelhofer T. Etgen B. Conrad Progression of early carotid atherosclerosis is only temporarily reduced after antibiotic treatment of Chlamydia pneumoniae seropositivity Circulation 109 2004 1010-1015
32. E. Gurfinkel G. Bozovich E. Beck E. Testa B. Livellara B. Mautner Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study [see comments] Eur Heart J 20 1999 121-127
33. J. Sinisalo K. Mattila M.S. Nieminen V. Valtonen M. Syrjala S. Sundberg et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production J Antimicrob Chemother 41 1998 85-92
34. J.T. Kuvin N. Gokce M. Holbrook L.M. Hunter A.R. Patel K.A. Sliney et al. Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function Am J Cardiol 91 2003 732-735
35. N. Parchure E.G. Zouridakis J.C. Kaski Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection Circulation 105 2002 1298-1303
36. M. Mosorin J. Juvonen F. Biancari J. Satta H.M. Surcel M. Leinonen et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: A randomized, double-blind, placebo-controlled pilot study J Vasc Surg 34 2001 606-610
37. S. Vammen J.S. Lindholt L. Ostergaard H. Fasting E.W. Henneberg Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion Br J Surg 88 2001 1066-1072
38. B. Axisa I.M. Loftus A.R. Naylor S. Goodall L. Jones P.R. Bell et al. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques Stroke 33 2002 2858-2864
39. G. Melissano F. Blasi G. Esposito P. Tarsia L. Dordoni C. Arosio et al. Chlamydia pneumoniae eradication from carotid plaques. Results of an open, randomised treatment study Eur J Vasc Endovasc Surg 18 1999 355-359
40. M. Leinonen P. Saikku Evidence for infectious agents in cardiovascular disease and atherosclerosis Lancet Infect Dis 2 2002 11-17
41. D.G. Bloemenkamp W.P. Mali B.C. Tanis F.R. Rosendaal M.A. van den Bosch J.M. Kemmeren et al. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women Atherosclerosis 163 2002 149-156
42. L.A. Jackson D.K. Stewart S.P. Wang D.B. Cooke T. Cantrell J.T. Grayston Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease [in process citation] J Antimicrob Chemother 44 1999 411-414
43. J. Gieffers W. Solbach M. Maass In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries Antimicrob Agents Chemother 42 1998 2762-2764
44. A. Kutlin P.M. Roblin M.R. Hammerschlag Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model Antimicrob Agents Chemother 46 2002 409-412
45. J. Gieffers H. Fullgraf J. Jahn M. Klinger K. Dalhoff H.A. Katus et al. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment Circulation 103 2001 351-356
46. A. Aceti G. Mazzacurati M. Amendolea A. Pennica B. Zechini M. Trappolini et al. Relation of C reactive protein to cardiovascular risk factors. H. pylori and C. pneumoniae infections may account for most acute coronary syndromes BMJ 313 1996 428-429
47. E. Adam J.L. Melnick J.L. Probtsfield B.L. Petrie J. Burek K.R. Bailey et al. High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis Lancet 2 1987 291-293
48. D.S. Siscovick S.M. Schwartz L. Corey J.T. Grayston R. Ashley S.P. Wang et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The cardiovascular health study [in process citation] Circulation 102 2000 2335-2340
49. C. Espinola-Klein H.J. Rupprecht S. Blankenberg C. Bickel H. Kopp G. Rippin et al. Impact of infectious burden on extent and long-term prognosis of atherosclerosis Circulation 105 2002 15-21
50. J.T. Grayston Background and current knowledge of Chlamydia pneumoniae and atherosclerosis J Infect Dis 181 Suppl 3 2000 S402-S410
51. P. Libby D. Egan S. Skarlatos Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research Circulation 96 1997 4095-4103